UBS reiterates Gilead Sciences stock rating on strong Yeztugo sales By Investing.com

Yeztugo combined January–February sales hit $100M with February up 56% MoM and IMS tracking ~90% capture since launch, implying March scripts around $58M and suggesting the company can hit ~ $145M consensus. Gilead (market cap $172.85B) trades at $138.74 (≈26% below UBS $175 PT) and announced acquisition of Ouro Medicines for up to $2.18B ($1.675B upfront + up to $500M milestones) adding OM336 to its inflammation pipeline. Multiple brokers reaffirmed bullish views (UBS $175 Buy, Deutsche Bank $155 Buy with Q1’26 sales est. ~$118M, Bernstein $160 Outperform, Truist $152 Buy) while Goldman Sachs stayed Neutral at $125.

Analysis

Early uptake patterns for the new long‑acting prevention agent imply a durable shift in patient preference that will change revenue cadence and service economics for clinics and payers. A move from more frequent to semi‑annual dosing materially reduces clinic administration events and ancillary revenue (labs, visit fees), shifting value capture from recurring touchpoints to per‑dose price and adherence advantages; that alters who benefits across the chain — manufacturers of delivery devices and cold‑chain logistics may see lower unit volumes but higher value per injection, while specialty clinics could lose repeat revenue.

The small acquisition adds optionality but is binary: meaningful valuation upside requires positive mid‑stage/late‑stage readthroughs over 12–36 months, while the contingent pay structure caps near‑term cash risk. Expect management to reallocate commercialization and BD bandwidth toward immunology, which could slow other franchises' launches or label expansions and compress medium‑term free cash flow if synergies are delayed.

Key tail risks live on three horizons: weeks–months for script capture volatility and payer contracting noise (use 4‑week rolling trends), quarters for realized revenue versus sell‑side forecasts as formularies and net pricing settle, and 1–3 years for trial readouts or safety signals that would reprice the OM336 optionality. Monitor PBM formulary decisions, initial real‑world adherence metrics, and any supply/cold‑chain constraints — each can flip the story quickly given the product's dosing cadence.

Consensus is optimistic on uptake; the overlooked counterpoint is that longer dosing both helps adherence and concentrates payer negotiation power (fewer high‑cost claims make each decision binary). That makes a calibrated, option‑led approach preferable to outright leverage to the equity until we see stable multi‑month capture rates and early payer contracts.

Key Decisions for Investors

• Long GILD (equity): Buy into a 6–12 month target window to capture continued launch momentum and M&A optionality; position size 1–3% of portfolio with a 10% stop‑loss. Rationale: asymmetric upside to $155–$175 if capture rates and payer access follow current trends; downside limited by high gross margins and diversified cash flow.
• Options call spread (directional, limited risk): Buy GILD Jan‑2027 $150/$220 call spread (or equivalent) sized for 0.5–1% of NAV. Risk/Reward: limited premium loss with ~3–5x upside to breakeven if positive cadence and OM336 upside materialize over 9–18 months.
• Hedge pair: Long GILD equity / Short XBI (or IBB) at 1:0.6 ratio for 3–9 months to isolate product launch upside from sector beta. Risk/Reward: reduces macro/biotech drawdowns while retaining idiosyncratic upside if Yeztugo capture remains strong.
• Event‑driven hedge (tail protection): Buy Jun‑2026 $120 puts or buy a 3–6 month put spread to guard against script deceleration or payer pushback. Use 0.25–0.5% NAV notional; this is cheap insurance against a rapid downside re‑rating from safety/payer events.